Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Non-Current Deffered Revenue (2024 - 2025)

Gossamer Bio's Non-Current Deffered Revenue history spans 2 years, with the latest figure at $29.6 million for Q4 2025.

  • For Q4 2025, Non-Current Deffered Revenue fell 23.83% year-over-year to $29.6 million; the TTM value through Dec 2025 reached $29.6 million, down 23.83%, while the annual FY2025 figure was $29.6 million, 23.83% down from the prior year.
  • Non-Current Deffered Revenue reached $29.6 million in Q4 2025 per GOSS's latest filing, up from $27.1 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $49.7 million in Q2 2024 to a low of $27.1 million in Q3 2025.